On December 12, 2022, Trinomab announced the appointment of Mr. Zhao Wengui as the general manager of marketing for Greater China (vice president level), responsible for development of the company's marketing strategies, sales plan and market development of products, product life cycle management and other related work.
Mr. Zhao Wengui has been working in the field of marketing in the pharmaceutical industry for more than 20 years. After college graduation, he has been holding multiple important positions in the well-known listed company "Kangzhe Pharmaceutical". From provincial and regional teams to the group marketing department and medical department, he has rich experience in business development, building efficient teams, marketing layout, enterprise strategy and commercialization. It covers the sales, marketing and medicine of the marketing system, and has extensive experience in strategic planning and business operation. Over the past 20 years, Mr. Zhao Wengui has accumulated experience covering the whole process of marketing strategy and annual marketing plan. Mr. Zhao has successfully achieved multiple strategic objectives and business cooperation in the past. With his outstanding management experience and ability to expand and innovate, Mr. Zhao Wengui had been an outstanding provincial manager as well as a regional manager, he also was the excellent lecturer of the company's talent echelon construction and the ambassador of corporate culture integration at for Kangzhe Pharmaceutical.
Mr. Zheng Weihong, co-founder, CEO and President of Trinomab, said:
Anti-tetanus toxin (TT) monoclonal antibody TNM002, a blockbuster new drug of Trinomab, is in an important sprint stage. It has formally reached to phase III clinical trials, and is expected to be filed for NDA for commercialization in 2023. At the present time, additional more innovative drugs will enter the clinical trials and commercialization stage in the near future. We are thrilled to add Mr. Zhao Wengui to our team at this critical stage of development. Based on his rich industry experience, Mr. Zhao Wengui will not only lead the brand upgrade of natural fully human antibody drugs, but also will start to develop Trinomab’s marketing strategies and sale plan from scratch. We believed that Mr. Zhao Wengui will be a strong addition to help Trinomab to advance more efficiently in the development and commercialization of innovative antibody drugs in company’s pipeline and accelerate the global strategic layout of Trinomab.
Mr. Zhao Wengui said:
It is a great honor to join Trinomab at this time. Trinomab is a company with strong capability in the discovery and development of innovative antibody drugs using its proprietary human monoclonal antibody discovery platform technology. I will leverage my marketing experience gained in the past 20 years, focus on the company's unique antibody drugs and anti-infective fields, formulate the company's commercialization strategy, build a marketing team of professionals to lay a solid foundation for the launch of new products. We will develop brand names for company’s products to strathen the core competitiveness of Trinomab to promote the global layout of the company.
About Trinomab
Trinomab Biotech Co., Ltd. is a clinical stage biopharmaceutical company with a global expansion perspective. The company is mainly engaged in R&D of novel fully native human mAb drugs. The core technology of the company is known as the fourth-generation antibody technology HitmAb®, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs as therapeutics against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.
Upholding the mission of “create clinical value”, TNM001 injection (anti-RSV long-acting monoclonal antibody) and TNM002 injection (anti-tetanus toxin monoclonal antibody), the core products of Trinomab have entered the clinical stage one after another. It is worth mentioning that TNM001 and TNM002 have obtained IND approvals in China and the United States. At present, TNM001 is in clinical phase Ib/IIa; TNM002 has officially entered phase III clinical trials, and has obtained the Breakthrough Therapy of CDE in China and the Fast Track Designation of FDA in the United States. In addition, a number of products are in the IND stage, with multiple early development projects are under continuous research and development.
Trinomab has completed several rounds of financing, investors include Gree Gold Investment, Kinggray Capital, Hillhouse Capital, CICC Capital, Efung Capital, CMB International Capital, Kangzhe Pharmaceutical, Wuxi Biologics, Zhuhai Jinhang Group etc. Trinomab is accelerating the commercialization of innovative drugs, launching a large number of international multi-center clinical trials, accelerating the implementation of the internationalization strategy, and serving global patients as soon as possible.
